C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
C4 Therapeutics (NASDAQ: CCCC) announced that its collaboration partner Biogen received FDA acceptance of the IND application for BIIB142, an IRAK4 degrader targeting autoimmune diseases. This marks a significant milestone in their strategic collaboration initiated in 2018.
The partnership combines C4T's expertise in targeted protein degradation with Biogen's drug development capabilities. C4T has delivered two development candidates to Biogen, who will handle future clinical development and commercialization. C4T will receive a $2 million milestone payment when Biogen begins dosing patients in the BIIB142 clinical trial.
C4 Therapeutics (NASDAQ: CCCC) ha annunciato che il suo partner di collaborazione Biogen ha ottenuto l'accettazione della FDA per la domanda IND relativa a BIIB142, un degrader di IRAK4 volto alle malattie autoimmuni. Si tratta di un importante traguardo nella loro collaborazione strategica avviata nel 2018.
La partnership unisce l'esperienza di C4T nella degradazione mirata delle proteine alle capacità di sviluppo farmaceutico di Biogen. C4T ha fornito due candidati di sviluppo a Biogen, che si occuperà dello sviluppo clinico futuro e della commercializzazione. C4T riceverà un pagamento milestone di 2 milioni di dollari quando Biogen inizierà la somministrazione ai pazienti nello studio clinico di BIIB142.
C4 Therapeutics (NASDAQ: CCCC) anunció que su socio de colaboración Biogen obtuvo la aceptación por parte de la FDA de la solicitud IND para BIIB142, un degradador de IRAK4 dirigido a enfermedades autoinmunes. Esto representa un hito importante en su colaboración estratégica iniciada en 2018.
La asociación combina la experiencia de C4T en degradación dirigida de proteínas con las capacidades de desarrollo de fármacos de Biogen. C4T ha entregado dos candidatos de desarrollo a Biogen, que se encargará del desarrollo clínico y la comercialización futuros. C4T recibirá un pago por hito de 2 millones de dólares cuando Biogen comience a dosificar a pacientes en el ensayo clínico de BIIB142.
C4 Therapeutics (NASDAQ: CCCC)는 협력 파트너인 Biogen이 자가면역질환을 표적으로 하는 BIIB142의 IND 신청을 FDA가 접수했다고 발표했습니다. 이는 2018년에 시작된 전략적 협력의 중요한 이정표입니다.
이번 파트너십은 표적 단백질 분해 분야의 C4T 전문성과 Biogen의 신약 개발 역량을 결합합니다. C4T는 두 개의 개발 후보물질을 Biogen에 제공했으며, Biogen이 향후 임상 개발 및 상용화를 담당합니다. Biogen이 BIIB142 임상시험에서 환자 투약을 시작하면 C4T는 200만 달러의 마일스톤 지급을 받게 됩니다.
C4 Therapeutics (NASDAQ: CCCC) a annoncé que son partenaire de collaboration Biogen a obtenu l'acceptation par la FDA de la demande IND pour BIIB142, un dégradeur d'IRAK4 ciblant les maladies auto-immunes. Il s'agit d'une étape importante dans leur collaboration stratégique lancée en 2018.
Le partenariat associe l'expertise de C4T en dégradation ciblée des protéines aux capacités de développement de médicaments de Biogen. C4T a fourni deux candidats au développement à Biogen, qui prendra en charge les futurs développements cliniques et la commercialisation. C4T recevra un paiement de jalon de 2 millions de dollars lorsque Biogen commencera à traiter des patients dans l'essai clinique BIIB142.
C4 Therapeutics (NASDAQ: CCCC) gab bekannt, dass sein Kollaborationspartner Biogen von der FDA die Annahme des IND-Antrags für BIIB142 erhalten hat, einen IRAK4-Degrader zur Behandlung autoimmuner Erkrankungen. Dies ist ein bedeutender Meilenstein in ihrer 2018 gestarteten strategischen Zusammenarbeit.
Die Partnerschaft verbindet C4Ts Fachwissen in gezielter Protein-Destruktion mit Biogens Entwicklungskompetenz. C4T hat Biogen zwei Entwicklungskandidaten übergeben; Biogen wird die weitere klinische Entwicklung und Kommerzialisierung übernehmen. Sobald Biogen mit der Dosierung von Patienten in der BIIB142-Studie beginnt, erhält C4T eine Meilensteinzahlung in Höhe von 2 Millionen US-Dollar.
- FDA acceptance of IND application for BIIB142, advancing the program to clinical stage
- Upcoming $2 million milestone payment upon clinical trial initiation
- Successful delivery of two development candidates to Biogen from the collaboration
- Strategic partnership leveraging complementary expertise in protein degradation and drug development
- Clinical development and commercialization control lies entirely with Biogen
- Limited financial upside with only $2 million milestone payment mentioned
Insights
Biogen's IND acceptance for CCCC-developed IRAK4 degrader triggers $2M milestone, validating their degradation platform and partnership approach.
C4 Therapeutics has achieved a significant milestone as its partner Biogen received FDA acceptance of an Investigational New Drug (IND) application for BIIB142, a targeted protein degrader aimed at IRAK4 for autoimmune diseases. This represents the second development candidate delivered under their collaboration established in 2018.
The advancement of BIIB142 toward clinical trials validates C4T's targeted protein degradation platform technology. Protein degradation represents an emerging therapeutic modality with potential advantages over traditional inhibitors, particularly for challenging targets like IRAK4, which plays a central role in inflammatory signaling pathways implicated in various autoimmune conditions.
From a financial perspective, C4T will receive a
This announcement highlights the company's strategic approach of leveraging partnerships with larger pharmaceutical companies to advance their technology platform while developing their wholly-owned pipeline. The validation from Biogen, a leader in neurological and autoimmune disease therapeutics, strengthens confidence in C4T's technological capabilities and business model.
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that its partner Biogen has had its investigational new drug (IND) application for BIIB142 accepted by the U.S. Food and Drug Administration (FDA). BIIB142 is a degrader of IRAK4 that Biogen intends to explore for therapeutic use in patients with autoimmune diseases.
“We are thrilled to see Biogen quickly advance the IRAK4 degrader that resulted from our collaboration toward the clinic in the hopes this molecule may bring a new treatment option to patients with autoimmune disease,” said Paige Mahaney, Ph.D., chief scientific officer of C4 Therapeutics. “Our long-standing collaboration with Biogen helped C4T build and deepen capabilities across our platform as we worked together to develop degraders for a broad range of target classes and therapeutic areas to reach a sizeable number of patients with unmet needs. We look forward to Biogen’s continued progress with BIIB142, as well as the second development candidate delivered under our collaboration.”
“Our collaboration with C4 Therapeutics has been both powerful and deeply productive, pairing C4T’s expertise in targeted protein degradation with Biogen’s scientific leadership and drug development capabilities,” said Jane Grogan, Ph.D., head of research at Biogen. “I’m proud that we have advanced this program based on a cutting-edge modality for a disease with high unmet need, and we see great promise in continuing to pioneer these types of investigational approaches.”
Under the terms of the strategic collaboration established in 2018, C4T provided expertise and research services in targeted protein degradation and Biogen provided scientific and drug development capabilities. C4T delivered two development candidates to Biogen under this collaboration. Biogen is responsible for all future clinical development and commercialization for these development candidates. C4T is entitled to receive a
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding the design and potential efficacy of our therapeutic approaches; and the potential timing of clinical development activities or the receipt of related milestone payments. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing, advancement and conduct of clinical studies by Biogen; the risk that this product candidate may not be successfully developed and commercialized; and the risk that we will receive future milestone or royalty payments related to the development of this product candidate. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law.
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
What is the significance of FDA accepting Biogen's IND application for BIIB142?
How much will C4 Therapeutics (CCCC) receive from Biogen for the BIIB142 milestone?
What is the partnership structure between C4 Therapeutics and Biogen?
What therapeutic area is BIIB142 targeting?
How many development candidates has C4 Therapeutics (CCCC) delivered to Biogen?
